tetano
Editor, Senior Moderator
Microb Pathog. 2020 May 5;146:104241. doi: 10.1016/j.micpath.2020.104241. [Epub ahead of print]
Study of combining virtual screening and antiviral treatments of the Sars-CoV-2 (Covid-19).
Khodadadi E[SUP]1[/SUP], Maroufi P[SUP]2[/SUP], Khodadadi E[SUP]3[/SUP], Esposito I[SUP]4[/SUP], Ganbarov K[SUP]5[/SUP], Espsoito S[SUP]6[/SUP], Yousefi M[SUP]7[/SUP], Zeinalzadeh E[SUP]8[/SUP], Kafil HS[SUP]9[/SUP].
Author information
Abstract
The recent epidemic outbreak of a novel human coronavirus called SARS-CoV-2 and causing the respiratory tract disease COVID-19 has reached worldwide resonance and a global effort is being undertaken to characterize the molecular features and evolutionary origins of this virus. Therefore, rapid and accurate identification of pathogenic viruses plays a vital role in selecting appropriate treatments, saving people's lives and preventing epidemics. Additionally, general treatments, coronavirus-specific treatments, and antiviral treatments useful in fighting COVID-19 are addressed. This review sets out to shed light on the SARS-CoV-2 and host receptor recognition, a crucial factor for successful virus infection and taking immune-informatics approaches to identify B- and T-cell epitopes for surface glycoprotein of SARS-CoV-2. A variety of improved or new approaches also have been developed. It is anticipated that this will assist researchers and clinicians in developing better techniques for timely and effective detection of coronavirus infection. Moreover, the genomic sequence of the virus responsible for COVID-19, as well as the experimentally determined three-dimensional structure of the Main protease (Mpro) is available. The reported structure of the target Mpro was described in this review to identify potential drugs for COVID-19 using virtual high throughput screening.
Copyright ? 2020 Elsevier Ltd. All rights reserved.
KEYWORDS:
COVID-19; Coronavirus; Epitopes; Immune-informatics; SARS-CoV-2
PMID:32387389DOI:10.1016/j.micpath.2020.104241
Study of combining virtual screening and antiviral treatments of the Sars-CoV-2 (Covid-19).
Khodadadi E[SUP]1[/SUP], Maroufi P[SUP]2[/SUP], Khodadadi E[SUP]3[/SUP], Esposito I[SUP]4[/SUP], Ganbarov K[SUP]5[/SUP], Espsoito S[SUP]6[/SUP], Yousefi M[SUP]7[/SUP], Zeinalzadeh E[SUP]8[/SUP], Kafil HS[SUP]9[/SUP].
Author information
Abstract
The recent epidemic outbreak of a novel human coronavirus called SARS-CoV-2 and causing the respiratory tract disease COVID-19 has reached worldwide resonance and a global effort is being undertaken to characterize the molecular features and evolutionary origins of this virus. Therefore, rapid and accurate identification of pathogenic viruses plays a vital role in selecting appropriate treatments, saving people's lives and preventing epidemics. Additionally, general treatments, coronavirus-specific treatments, and antiviral treatments useful in fighting COVID-19 are addressed. This review sets out to shed light on the SARS-CoV-2 and host receptor recognition, a crucial factor for successful virus infection and taking immune-informatics approaches to identify B- and T-cell epitopes for surface glycoprotein of SARS-CoV-2. A variety of improved or new approaches also have been developed. It is anticipated that this will assist researchers and clinicians in developing better techniques for timely and effective detection of coronavirus infection. Moreover, the genomic sequence of the virus responsible for COVID-19, as well as the experimentally determined three-dimensional structure of the Main protease (Mpro) is available. The reported structure of the target Mpro was described in this review to identify potential drugs for COVID-19 using virtual high throughput screening.
Copyright ? 2020 Elsevier Ltd. All rights reserved.
KEYWORDS:
COVID-19; Coronavirus; Epitopes; Immune-informatics; SARS-CoV-2
PMID:32387389DOI:10.1016/j.micpath.2020.104241